

IMPLEMENTING TUBERCULOSIS DIAGNOSTICS

Policy framework



World Health
Organization

IMPLEMENTING TUBERCULOSIS DIAGNOSTICS

Policy framework



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Implementing tuberculosis diagnostics. Policy framework.

1. World Health Organization.

ISBN 978 92 4 150861 2

Subject headings are available from WHO institutional repository

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by GPS Publishing

WHO/HTM/TB/2015.11

Contents

ABBREVIATIONS	VI
1. INTRODUCTION	1
2. PURPOSE OF THIS DOCUMENT	3
3. WHO SHOULD USE THIS DOCUMENT?	3
4. WHO'S PROCESS FOR DEVELOPING POLICIES ON TB DIAGNOSTICS	4
5. COMPONENTS OF A HIGH-QUALITY NETWORK OF TB LABORATORIES	6
5.1 PLANNING FOR THE IMPLEMENTATION OF DIAGNOSTIC SERVICES	6
5.2 ENSURING APPROPRIATE LABORATORY INFRASTRUCTURE AND ITS MAINTENANCE, AS WELL AS BIOSAFETY MEASURES	6
5.3 VALIDATING AND MAINTAINING EQUIPMENT	7
5.4 COLLECTING, TRANSPORTING AND REFERRING SPECIMENS	7
5.5 MANAGING LABORATORY EQUIPMENT AND SUPPLIES	9
5.6 IMPLEMENTING SYSTEMS TO MANAGE LABORATORY INFORMATION AND DATA	9
5.7 IMPLEMENTING QUALITY-MANAGEMENT SYSTEMS FOR A LABORATORY	10
5.8 ENSURING APPROPRIATE STRATEGIES FOR MANAGING HUMAN RESOURCES AND ADEQUATE FUNDING FOR HUMAN RESOURCES	12
6. USING DIAGNOSTIC TECHNIQUES IN A TIERED LABORATORY NETWORK	13
7. WHO'S RECOMMENDED TECHNIQUES FOR DIAGNOSING TB	14
7.1 MICROSCOPY	14
7.1.1 CONVENTIONAL LIGHT MICROSCOPY	14
7.1.2 LIGHT-EMITTING DIODE FLUORESCENCE MICROSCOPY	15
7.2 CULTURE AND SPECIES IDENTIFICATION	15
7.3 DRUG-SUSCEPTIBILITY TESTING	16
7.3.1 DRUG-SUSCEPTIBILITY TESTING FOR FIRST-LINE ANTI-TB AGENTS	17
7.3.2 DRUG-SUSCEPTIBILITY TESTING FOR SECOND-LINE ANTI-TB AGENTS	18
7.3.3 NON-COMMERCIAL METHODS	18

7.4 MOLECULAR TESTING	19
7.4.1 LINE-PROBE ASSAYS	19
7.4.2 XPERT MTB/RIF ASSAY	20
7.5 TESTING FOR LATENT TB INFECTION	21
8. TECHNIQUES NOT RECOMMENDED BY WHO FOR THE DIAGNOSIS OF ACTIVE TB	23
8.1 COMMERCIAL SERODIAGNOSTIC TESTS FOR DIAGNOSIS OF ACTIVE TB DISEASE	23
8.2 IGRA FOR DIAGNOSIS OF ACTIVE TB DISEASE	23
9. ALGORITHMS FOR DIAGNOSTIC TESTING	24
10. REFERENCES	31
11. ANNEXES	35
ANNEX 1. SUMMARY OF CHARACTERISTICS OF AND LABORATORY REQUIREMENTS FOR WHO'S RECOMMENDED TECHNIQUES FOR DIAGNOSING TB	35
ANNEX 2. WHO GLOBAL TUBERCULOSIS PROGRAMME GUIDANCE ON TEMPORARY TB CONTROL MEASURES IN EBOLA-AFFECTED COUNTRIES	36

Acknowledgements

This document was prepared by Christopher Gilpin and Alexei Korobitsyn from the Laboratories, Diagnostics and Drug Resistance unit of WHO's Global TB Programme.

The following individuals from the WHO Global TB Programme also contributed to the writing and review of this manual: Dennis Falzon, Haileyesus Getahun, Malgosia Grzemska, Jean de Dieu Iragena, Ernesto Jaramillo, Knut Lönnroth, Alberto Matteelli, Fuad Mirzayev, Ikushi Onozaki, Mario Raviglione, Wayne Van Gemert, Fraser Wares and Karin Weyer.

The development and publication of this document has been made possible with the support of the United States Agency for International Development (USAID). Funding through the USAID-WHO Consolidated Grant No. GHA-G-00-09-00003/US 2013 0584 is gratefully acknowledged.

Cover page: The cover design incorporates a figure adapted with permission from the publication by Hongtai Zhang et al. Genome sequencing of 161 *Mycobacterium tuberculosis* isolates from China identifies genes and intergenic regions associated with drug resistance. *Nature Genetics*, 2013, 45:1255–1260
(available at: http://www.nature.com/ng/journal/v45/n10/full/ng.2735.html?WT.ec_id=NG-201310).

Abbreviations

AFB	acid-fast bacilli
CRI	colorimetric redox indicator
DST	drug-susceptibility testing
FIND	Foundation for Innovative New Diagnostics
GLI	Global Laboratory Initiative
GRADE	Grading of Recommendations Assessment, Development and Evaluation
IGRA	interferon-gamma release assay
ISO	International Organization for Standardization
LED	light-emitting diode
LPA	line-probe assay
LTBI	latent TB infection
MDR-TB	multidrug-resistant tuberculosis
MODS	microscopic observation drug-susceptibility assay
MTBC	<i>Mycobacterium tuberculosis complex</i>
NAAT	nucleic acid amplification test
NRA	nitrate reductase assay
NTM	non-tuberculosis mycobacteria
PCR	polymerase chain reaction
QMS	quality-management system
<i>rpoB</i>	gene encoding for the β -subunit of the DNA-dependent RNA polymerase of <i>Mycobacterium tuberculosis</i>
RR-TB	rifampicin-resistant tuberculosis
SLIPTA	stepwise laboratory quality improvement process towards accreditation
SLMTA	strengthening laboratory management towards accreditation
SOP	standard operating procedure
STAG-TB	Strategic and Technical Advisory Group for Tuberculosis
TB	tuberculosis
TST	tuberculin skin test
WHO	World Health Organization
XDR-TB	extensively drug-resistant tuberculosis

Introduction

Tuberculosis (TB) laboratories play a critical part in national TB programmes, providing clinicians with invaluable information that is used to diagnose and guide the care of patients. Because of the specialized nature of the different technical procedures needed to diagnose TB, and the need for quality assurance and effective laboratory management, TB control programmes require a tiered network of laboratories in which different tiers use complementary diagnostic tools and mechanisms for referring specimens. Establishing, equipping and maintaining a laboratory network to ensure that there are timely and universal access to quality-assured diagnostics is challenging, complex and expensive, and the following core elements must be addressed simultaneously:

- planning for the implementation of diagnostic services;
- developing laboratory infrastructure and plans for maintaining the infrastructure, as well as implementing appropriate biosafety measures;
- developing schedules for equipment validation and maintenance;
- establishing mechanisms for specimen collection, transport and referral;
- establishing systems for managing

resistant TB and TB associated with HIV. An unprecedented effort to improve and expand the capacity of TB laboratories is under way, coordinated by the World Health Organization's (WHO's) Global TB Programme and with the active involvement of the Global Laboratory Initiative (GLI), a working group of the Stop TB Partnership (for more information, see <http://www.stoptb.org/wg/gli>).

The targets for laboratory strengthening in *The global plan to stop TB 2011–2015* include ensuring:¹

- there is 1 microscopy centre per 100 000 population (for smear examinations for acid-fast bacilli [AFB]);
- there is 1 laboratory per 5 000 000 population to perform culture testing;
- that 50% of tests for drug resistance for new TB patients and more than 90% of tests for previously treated patients are done using rapid TB diagnostic tests.

However, with the roll-out of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, United States), the number of microscopy centres and facilities offering culture and drug-susceptibility testing (DST) will need to be adjusted depending on the extent of the roll-out in different settings and

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?>